ClinicalTrials.gg
CompletedNCT03533114Updated Nov 24, 2021Results posted

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

A Phase 3 interventional study of JZP-258 and Placebo Oral Solution in Idiopathic Hypersomnia, sponsored by Jazz Pharmaceuticals. Completed at 63 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Enrollment
8th of 27
154 · median 100
Started
2018
with 2 others
Phase 3
6 of 30
2 open now
Registered
7th of 30
by date
Lead sponsor
3 of 30
Jazz Pharmaceuticals

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2018, is one of 6 in phase 3, and was the 7th registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

This is a study of the efficacy and safety of JZP-258, an oxybate mixed-salts oral solution being developed as a low sodium alternative product for Xyrem.

03

Conditions studied

  • Idiopathic Hypersomnia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 18 and 75 years of age, inclusive, at the time of consent.
  2. Have a primary diagnosis of IH according to the International Classification of Sleep Disorders ICSD-2 or ICSD-3 criteria.
  3. At the Screening Visit and the Baseline Visit, subjects who are not on Xyrem at study entry must have ESS scores ≥ 11 (as assessed with a look-back period of 1 week).
  4. If currently treated with Xyrem, must have documented clinical improvement of EDS after the initiation of Xyrem per Investigator's clinical judgment.
  5. Average nightly total sleep time of ≥ 7 hours, per subject history. Average nightly total sleep time will be confirmed by Investigator's review of sleep diaries collected during the final 2 weeks of the Screening Period.
  6. If currently treated with stimulants and / or alerting agents or nicotine replacement therapy, must have been taking the same regimen and dose for at least 2 months prior to screening and must agree to take the same dose leading up to and throughout the Double-blind Randomized Withdrawal Period.
  7. Have used a medically acceptable method of for at least 2 months prior to the first dose of study drug and consent to use a medically acceptable method of contraception from the first dose of study drug, throughout the entire study period, and for 90 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Hypersomnia due to another medical, behavioral, or psychiatric disorder condition.
  2. Evidence of untreated or inadequately treated sleep-disordered breathing.
  3. parasomnias (eg, sleep walking, rapid eye movement sleep behavior disorder, etc.).
  4. Current or past (within 1 year) major depressive episode according to criteria. Patients with depression under control are allowed per the judgment of the Investigator or the treating physician and the anti-depressant treatment has to be stable for at least 6 months prior to Screening and remain stable for the duration of the study.
  5. Current suicidal risk as determined from history by presence of active suicidal ideation as indicated by positive response to item #4 or #5 on C-SSRS, or any history of suicide attempt.
  6. Occupation requiring nighttime shift work or variable shift work with early work start times or other occupations that could affect the safety of the subject per the judgment of the Investigator.
  7. Treatment or planned treatment with any CNS sedating agents, including but not limited to benzodiazepines or other sedating anxiolytics, sedating antidepressants, hypnotics, sedatives, neuroleptics, opoids, barbiturates, phenytoin, melatonin, ethosuximide, medications containing valproic acid or its sodium salt, or any other medication in which the subject experiences sedation are prohibited during the study. Treatment must have been discontinued within 2 weeks or 5 half-lives, whichever is longer, prior to enrollment. The Investigator must ensure that discontinuation from these medications is medically supervised. Subjects must abstain from these medications during the study.
  8. Current or past substance use disorder (including alcohol) according to DSM-5 criteria, or the subject is unwilling to refrain from consuming alcohol, cannabinoids, or prohibited medications during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    JZP-258

    JZP-258 at the stable dose and regimen for 2 weeks.

    Drug: JZP-258

  • Placebo comparator
    Placebo

    Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.

    Drug: Placebo Oral Solution

Interventions

  • Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.

  • DrugPlacebo Oral Solution

    Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.

06

What researchers measure

Primary outcomes

  1. Change in Epworth Sleepiness Scale (ESS) Score

    The ESS is a 8-item self reported questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A positive mean change value indicates an increase in score from the end of the stable dose period and worsened daytime sleepiness. A higher ESS score (above 10) reflects a greater average sleep propensity in daily life (ASP) , or daytime sleepiness.

    Time frame: Change from the end of the Stable Dose Period to the end of the Double-blind Randomized Withdrawal Period (DBRW) (2 Weeks)

Secondary outcomes

  1. Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc)

    The Patient Global Impression - Change (PGIc) scale was completed by the participant. The PGI-C scale rated the participant's condition at a specified time point on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The PGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a PGIc rating of 5, 6, or 7.

    Time frame: At the end of the DBRW Period (2 Weeks)

  2. Change in Total Score on the Idiopathic Hypersomnia Severity Scale (IHSS)

    The IHSS is a 14-item self-reported questionnaire assessing the severity of IH symptoms of excessive sleepiness, prolonged sleep duration, cognitive impairment and sleep inertia. Total scores can range from 0 to 50, with higher scores indicating a greater severity or frequency of symptoms.

    Time frame: Change from the end of the Stable Dose Period to the end of the DBRW Period (2 Weeks)

  3. Percentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc)

    The CGIc scale is a 7-point Likert-type scale that rates the Investigator's impression of any change in the severity of the participant's condition at a specified time point. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The CGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a CGIc rating of 5, 6, or 7.

    Time frame: At the end of the DBRW Period (2 Weeks)

  4. Change in Total Score on the Functional Outcomes of Sleep Questionnaire (FOSQ-10)

    The FOSQ-10 is a short version of the original FOSQ-30 instrument, which is a disease specific quality of life questionnaire to determine functional status in adults. Measures are designed to assess the impact of disorders of excessive sleepiness on multiple activities of everyday living and the extent to which these activities are improved by effective treatment. The questionnaire has a 4-point Likert response format (e.g., 1= extreme difficulty, 2= moderate difficulty, 3=a little difficulty, and 4 =no difficulty). FOSQ-10 total score is calculated by first taking the mean of the items for each subscale with more than 1 item completed and then taking the mean across the non-missing 5 subscales (General Productivity, Activity Level, Vigilance, Social Outcomes, Intimacy and Sexual Relationship) multiplied by 5. The score ranges from a minimum of 5 points to a maximum of 20 points, with higher scores indicating better functional status.

    Time frame: Change from the end of the Stable Dose Period to the end of the DBRW Period (2 Weeks)

07

Results

Posted Nov 24, 2021

Participant flow

The safety population is categorized according to the presence or absence of medications used to treat IH symptoms at the time of study baseline.

Overall
Participant flow — Overall
MilestoneOn Baseline IH MedicationTreatment Naive
Started8866
Completed5738
Not completed3128
Withdrew: Adverse event1611
Withdrew: Consent withdrawal by participant76
Withdrew: Lack of efficacy53
Withdrew: Lost to follow-up11
Withdrew: Physician decision02
Withdrew: Protocol deviation11
Withdrew: Failure to meet randomization criteria12
Withdrew: Non-compliance with study drug01
Withdrew: Other01
Open Label Titration and Optimization
Participant flow — Open Label Titration and Optimization
MilestoneOn Baseline IH MedicationTreatment Naive
Started8866
Completed7253
Not completed1613
Withdrew: Adverse event118
Withdrew: Consent withdrawal by participant21
Withdrew: Lack of efficacy31
Withdrew: Lost to follow-up01
Withdrew: Protocol deviation01
Withdrew: Non-compliance with study drug01
Stable Dose
Participant flow — Stable Dose
MilestoneOn Baseline IH MedicationTreatment Naive
Started7152
Completed6950
Not completed22
Withdrew: Adverse event02
Withdrew: Consent withdrawal by participant10
Withdrew: Lack of efficacy10
Double Blind Randomized-Withdrawal
Participant flow — Double Blind Randomized-Withdrawal
MilestoneOn Baseline IH MedicationTreatment Naive
Started6947
Jzp-258570
Placebo059
Completed6746
Not completed21
Withdrew: Adverse event11
Withdrew: Failure to meet randomization criteria10
Open-Label Safety Extension
Participant flow — Open-Label Safety Extension
MilestoneOn Baseline IH MedicationTreatment Naive
Started6541
Completed5738
Not completed83
Withdrew: Adverse event30
Withdrew: Consent withdrawal by participant23
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up10
Withdrew: Protocol deviation10

Outcome measures

PrimaryChange in Epworth Sleepiness Scale (ESS) Score

The ESS is a 8-item self reported questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A positive mean change value indicates an increase in score from the end of the stable dose period and worsened daytime sleepiness. A higher ESS score (above 10) reflects a greater average sleep propensity in daily life (ASP) , or daytime sleepiness.

Time frame:
Change from the end of the Stable Dose Period to the end of the Double-blind Randomized Withdrawal Period (DBRW) (2 Weeks)
Reported as:
Mean · score on a scale
Change in Epworth Sleepiness Scale (ESS) Score
score on a scaleJZP-258Placebo
Change in Epworth Sleepiness Scale (ESS) Score0.7 ± 3.227.4 ± 5.16
SecondaryPercentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc)

The Patient Global Impression - Change (PGIc) scale was completed by the participant. The PGI-C scale rated the participant's condition at a specified time point on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The PGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a PGIc rating of 5, 6, or 7.

Time frame:
At the end of the DBRW Period (2 Weeks)
Reported as:
Number · participants
Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc)
participantsJZP-258Placebo
Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc)1252
SecondaryChange in Total Score on the Idiopathic Hypersomnia Severity Scale (IHSS)

The IHSS is a 14-item self-reported questionnaire assessing the severity of IH symptoms of excessive sleepiness, prolonged sleep duration, cognitive impairment and sleep inertia. Total scores can range from 0 to 50, with higher scores indicating a greater severity or frequency of symptoms.

Time frame:
Change from the end of the Stable Dose Period to the end of the DBRW Period (2 Weeks)
Reported as:
Median · score on a scale
Change in Total Score on the Idiopathic Hypersomnia Severity Scale (IHSS)
score on a scaleJZP-258Placebo
Change in Total Score on the Idiopathic Hypersomnia Severity Scale (IHSS)0.0 (-8 to 24)14.0 (-2 to 38)
SecondaryPercentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc)

The CGIc scale is a 7-point Likert-type scale that rates the Investigator's impression of any change in the severity of the participant's condition at a specified time point. The participant was rated on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The CGIc scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Worsened condition was defined as a CGIc rating of 5, 6, or 7.

Time frame:
At the end of the DBRW Period (2 Weeks)
Reported as:
Number · participants
Percentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc)
participantsJZP-258Placebo
Percentage of Participants Reported as Worse on the Clinical Global Impression of Change (CGIc)1252
SecondaryChange in Total Score on the Functional Outcomes of Sleep Questionnaire (FOSQ-10)

The FOSQ-10 is a short version of the original FOSQ-30 instrument, which is a disease specific quality of life questionnaire to determine functional status in adults. Measures are designed to assess the impact of disorders of excessive sleepiness on multiple activities of everyday living and the extent to which these activities are improved by effective treatment. The questionnaire has a 4-point Likert response format (e.g., 1= extreme difficulty, 2= moderate difficulty, 3=a little difficulty, and 4 =no difficulty). FOSQ-10 total score is calculated by first taking the mean of the items for each subscale with more than 1 item completed and then taking the mean across the non-missing 5 subscales (General Productivity, Activity Level, Vigilance, Social Outcomes, Intimacy and Sexual Relationship) multiplied by 5. The score ranges from a minimum of 5 points to a maximum of 20 points, with higher scores indicating better functional status.

Time frame:
Change from the end of the Stable Dose Period to the end of the DBRW Period (2 Weeks)
Reported as:
Median · score on a scale
Change in Total Score on the Functional Outcomes of Sleep Questionnaire (FOSQ-10)
score on a scaleJZP-258Placebo
Change in Total Score on the Functional Outcomes of Sleep Questionnaire (FOSQ-10)-0.08 (-8.5 to 4.5)-4.17 (-12.5 to 1.3)

Adverse events

Collected over Adverse Events (AEs) and Serious Adverse Events (SAEs) were recorded from the time on or after the first dose of study drug, including adverse events that occurred until 30 days after the last dose date up to 42 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
On Baseline IH Medication0/88 (0%)2/88 (2.3%)64/88 (72.7%)
Treatment Naive0/66 (0%)2/66 (3%)39/66 (59.1%)
JZP-0580/154 (0%)4/154 (2.6%)97/154 (63%)
Placebo0/59 (0%)0/59 (0%)10/59 (16.9%)
Most frequent serious events
Most frequent serious events
EventOn Baseline IH MedicationTreatment NaiveJZP-058Placebo
PyelonephritisInfections and infestations0/881/661/1540/59
SyncopeNervous system disorders0/881/661/1540/59
NephrolithiasisRenal and urinary disorders0/881/661/1540/59
Non-cardiac chest painGeneral disorders1/880/661/1540/59
RhabdomyolysisMusculoskeletal and connective tissue disorders1/880/661/1540/59
Most frequent other events
Showing 10 of 24
Most frequent other events
EventOn Baseline IH MedicationTreatment NaiveJZP-058Placebo
NauseaGastrointestinal disorders21/8813/6634/1541/59
HeadacheNervous system disorders15/8812/6627/1542/59
VomitingGastrointestinal disorders15/883/6617/1542/59
DizzinessNervous system disorders8/8811/6619/1540/59
InsomniaPsychiatric disorders13/884/6611/1546/59
DiarrhoeaGastrointestinal disorders11/883/6612/1542/59
AnxietyPsychiatric disorders10/888/6617/1541/59
Decreased appetiteMetabolism and nutrition disorders7/887/6614/1540/59
TremorNervous system disorders9/880/669/1540/59
Dry mouthGastrointestinal disorders8/882/6610/1540/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)On Baseline IH MedicationTreatment NaïveTotal
Mean41.0 ± 13.3739.4 ± 14.2540.3 ± 13.73
Sex: Female, Male
Sex: Female, Male(Participants)On Baseline IH MedicationTreatment NaïveTotal
Female6540105
Male232649
Race (NIH/OMB)
Race (NIH/OMB)(Participants)On Baseline IH MedicationTreatment NaïveTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander011
Black or African American549
White7653129
More than one race011
Unknown or Not Reported7714
Region of Enrollment
Region of Enrollment(participants)On Baseline IH MedicationTreatment NaïveTotal
North America6935104
Europe193150
08

Study locations

63 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • Wright Clinical Research, LLC
    Birmingham, Alabama 35243, United States
  • Coastal Clinical Research
    Mobile, Alabama 36608, United States
  • Mayo Clinic Building
    Phoenix, Arizona 85054, United States
  • Southern California Institute for Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Stanford Sleep Medicine Center
    Redwood City, California 94063, United States
  • SDS Clinical Trials, Inc.
    Santa Ana, California 92705, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Delta Waves, Inc.
    Colorado Springs, Colorado 80918, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • Bio-Medical Research, LLC
    Miami, Florida 33184, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • NeuroTrials Research
    Atlanta, Georgia 30342, United States
  • Sleep Practitioners, LLC
    Macon, Georgia 31210, United States
  • SleepCare Research Institute d/b/a Clinical Research
    Stockbridge, Georgia 30281, United States
  • Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Baystate Wesson Sleep Clinic
    Springfield, Massachusetts 01199, United States
  • Bronson Methodist Hospital
    Kalamazoo, Michigan 49007, United States
  • Clinical Neurophysiology Services, P.C.
    Sterling Heights, Michigan 48314, United States
  • Minnesota Lung Center
    Minneapolis, Minnesota 55435, United States
  • Clayton Sleep Institute, LLC
    Saint Louis, Missouri 63146, United States
  • Montefiore Medical Center/Sleep-Wake Disorders Center
    Bronx, New York 10467, United States
  • American Health Research
    Charlotte, North Carolina 28207, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Research Carolina
    Huntersville, North Carolina 28078, United States
  • Clinical Research of Lake Norman
    Mooresville, North Carolina 28117, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • Intrepid Research
    Cincinnati, Ohio 45245, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio Sleep Medicine and Neuroscience Institute
    Dublin, Ohio 43017, United States
  • Lynne Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Abington Neurological Associates
    Willow Grove, Pennsylvania 19090, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201, United States
  • Clinical Research of Charleston
    Mount Pleasant, South Carolina 29464, United States
  • Neurology Clinic, PC
    Cordova, Tennessee 38018, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Anima Research Center
    Alken, 3570, Belgium
  • Antwerp University Hospital
    Edegem, 2650, Belgium
  • CHU UCL Namur site de Sainte Elisabeth
    Namur, 5000, Belgium
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 50333, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha, 128 21, Czechia
  • Nemocnice Ceske Budejovice a.s.
    České Budějovice, 370 01, Czechia
  • VitalMed Oy
    Helsinki, 00240, Finland
  • CHU de Grenoble - Hôpital Michallon
    Grenoble, 38043, France
  • Hopital Roger Salengro
    Lille, 59037, France
  • Hopital Gui de Chauliac
    Montpellier, 34295, France
  • CHU Nantes - Hopital Nord Laënnec
    Nantes, 44093, France
  • Hopital Pitie-Salpetriere
    Paris, 75651, France
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, 80-952, Poland
  • Osrodek Badan Klinicznych CROMED
    Poznań, 61-505, Poland
  • lnstytut Psychiatrii i Neurologii, Zaklad Neurofizjologii Klinicznej
    Warsaw, 02-957, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Vithas Nuestra Señora de America
    Madrid, 28043, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Hospital Universitario Araba
    Vitoria, 01009, Spain
  • Royal Infirmary of Edinburgh
    Edinburgh, EH16 4SA, United Kingdom
09

References and documents

Publications

  • Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, Morse AM, Sonka K, Thorpy MJ, Mignot E, Chandler P, Parvataneni R, Black J, Sterkel A, Chen D, Skobieranda F, Bogan RK. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022 Jan;21(1):53-65. doi: 10.1016/S1474-4422(21)00368-9. PubMed 34942138 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jun 2020, 18 months.

Results were first posted in Nov 2021, 1 year 5 months after primary completion. A results delay was requested in Jun 2021.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2018
First posted
May 22, 2018
StartActual
Nov 27, 2018
Primary completionActual
Jun 12, 2020
CompletionActual
Dec 18, 2020
Results delay requested
Jun 4, 2021
Results first posted
Nov 24, 2021
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03533114
Responsible party
Sponsor
First posted
May 22, 2018
Start date
Nov 27, 2018
Primary completion
Jun 12, 2020
Completion
Dec 18, 2020
Results posted
Nov 24, 2021
Last update
Nov 24, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JZP258

Start the discussion